LIGAND PHARMACEUTICALS INC director Martine Zimmermann reported routine equity compensation and related tax withholding. She received 836 restricted stock units, each convertible into one share of common stock, granted by the board on June 5, 2026. These RSUs fully vest on the earlier of the next annual stockholder meeting or the first anniversary of the grant date. The company also granted her non-qualified stock options for 2,938 shares at an exercise price of $237.00 per share, with the same vesting schedule and expiration in 2036. To cover taxes on RSU settlement, 182 shares of common stock were withheld, a non-market disposition. After these transactions, she directly holds 5,097 common shares and 2,938 options.
Sabba Stephen L reported acquisition or exercise transactions in this Form 4 filing.
Ligand Pharmaceuticals director Stephen L. Sabba received new equity awards. On June 5, 2026, he was granted 836 restricted stock units, each representing one share of common stock, and 2,938 non-qualified stock options with a strike price of $237.00 per share.
Both the RSUs and options fully vest on the earlier of the company’s next annual stockholder meeting following the grant date or the first anniversary of the grant date. Following the stock grant, Sabba directly holds 33,629 shares of Ligand common stock, plus the newly granted options expiring on June 5, 2036.
LIGAND PHARMACEUTICALS INC director John L. Lamattina received equity awards from the board on June 5, 2026. He was granted 836 restricted stock units, each representing one share of common stock, increasing his direct common stock holdings to 31,560 shares.
He was also granted a Non-Qualified Stock Option for 2,938 shares of common stock at an exercise price of 237.0000 per share, expiring on June 5, 2036. Both the RSUs and the option award fully vest on the earlier of the next annual meeting of company stockholders following the grant date or the first anniversary of the grant date.
Ligand Pharmaceuticals director John W. Kozarich received new equity awards as part of his board compensation. On June 5, 2026, he was granted 836 restricted stock units, each representing one share of common stock, and a non-qualified stock option for 2,938 shares at an exercise price of $237.00 per share. Both awards fully vest on the earlier of the company’s next annual stockholder meeting following the grant date or the first anniversary of the grant date. Following these grants, Kozarich directly holds 42,622 shares of Ligand common stock.
Ligand Pharmaceuticals director Jason Haas received equity awards as part of board compensation. He acquired 836 restricted stock units, each representing one share of common stock, bringing his direct common stock holdings to 7,442 shares. He also received a non-qualified stock option for 2,938 shares at an exercise price of $237 per share, expiring on June 5, 2036. Both the RSUs and options fully vest on the earlier of the company’s next annual stockholder meeting following the grant date or the first anniversary of the June 5, 2026 grant.
Ligand Pharmaceuticals director Nancy Ryan Gray received new equity awards. She was granted 836 restricted stock units of common stock, which fully vest on the earlier of the next annual stockholder meeting or the first anniversary of the June 5, 2026 grant date.
Gray was also granted a non-qualified stock option for 2,938 shares of common stock at an exercise price of $237.00 per share, expiring on June 5, 2036. Following these grants, she holds 8,930 shares of common stock directly and 2,938 outstanding stock options.
Ligand Pharmaceuticals Incorporated reported the results of its 2026 annual stockholder meeting. Stockholders elected eight directors for terms expiring at the 2027 annual meeting, with support levels generally above 16.2 million votes for each nominee.
Investors ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 18,526,515 votes for and 257,924 against. Stockholders also approved a non-binding advisory resolution on executive compensation and an amendment and restatement of the Company’s 2002 Stock Incentive Plan, with 16,497,712 and 16,643,281 votes for each proposal, respectively.
Ligand Pharmaceuticals’ CLO and Secretary Andrew Reardon reported a set of planned insider trades in company common stock. On June 1, 2026, he exercised employee stock options for 5,000 shares at an exercise price of $52.27 per share, converting them into common stock.
On the same date, he executed open‑market sales totaling 5,000 shares of common stock in multiple transactions, at reported weighted‑average prices that include $230.41, $229.47, $228.57 and $223.95 per share. After these transactions, he directly holds 41,382 shares of Ligand common stock. The filing notes that these trades were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 24, 2025.
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza exercised employee stock options to acquire 1,736 shares of Common Stock on May 27, 2026. He exercised 972 options at an exercise price of $52.84 per share and 764 options at $63.62 per share. Following these transactions, he directly holds 27,679 Common Shares. The filing also shows 17,407 employee stock options remaining outstanding at a $63.62 exercise price, with expirations in 2032, reflecting routine compensation-related equity activity rather than open‑market buying or selling.